JAMA Neurology has published data from a Phase III trial of Fintepla (fenfluramine), the anti-seizure med developed by Brussels, Belgium-based drugmaker UCB (Euronext: UCB).
UCB is testing the oral medication as an adjunct to patients’ existing anti-epileptic treatment regimen, for seizures associated with Lennox-Gastaut syndrome (LGS).
LGS is a severe childhood-onset condition which causes seizures that are highly-resistant to treatment with existing medications. It also causes serious impairment of cognitive and motor functions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze